We are live on ! Find out more
SLXP

SALIX PHARMACEUTICALS LTD DEL
SLXP

Delisted

SLXP was delisted on the 31st of March, 2015.

308 hedge funds and large institutions have $8.26B invested in SALIX PHARMACEUTICALS LTD DEL in 2014 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 109 increasing their positions, 127 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more call options, than puts

Call options by funds: $199M | Put options by funds: $81.4M

21% more capital invested

Capital invested by funds: $6.82B → $8.26B (+$1.43B)

1% more funds holding

Funds holding: 304308 (+4)

9% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 46

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

14% less repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 127

Holders
308
Holders Change
+4
Holders Change %
+1.32%
% of All Funds
8.85%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.26%
New
50
Increased
109
Reduced
127
Closed
46
Calls
$199M
Puts
$81.4M
Net Calls
+$117M
Net Calls Change
+$65.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$871M -$1.8M -16,250 -0.2%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$823M -$132M -1,190,004 -15%
Vanguard Group
3
Vanguard Group
Pennsylvania
$482M -$23.2M -210,223 -5%
Viking Global Investors
4
Viking Global Investors
Connecticut
$356M +$148M +1,337,537 +86%
BFA
5
BlackRock Fund Advisors
California
$330M +$8.31M +75,160 +3%
TCIM
6
TIAA CREF Investment Management
New York
$246M +$92.8M +839,718 +73%
Bank of New York Mellon
7
Bank of New York Mellon
New York
$241M -$38.7M -349,687 -15%
State Street
8
State Street
Massachusetts
$236M +$2.02M +18,309 +1%
VAM
9
Visium Asset Management
New York
$224M +$5.57M +50,433 +3%
BIT
10
BlackRock Institutional Trust
California
$217M -$13.6M -122,859 -7%
Ameriprise
11
Ameriprise
Minnesota
$215M +$5.63M +50,977 +3%
TCM
12
TimesSquare Capital Management
New York
$168M -$34M -307,450 -18%
Federated Hermes
13
Federated Hermes
Pennsylvania
$150M -$23.8M -215,278 -15%
Citadel Advisors
14
Citadel Advisors
Florida
$134M +$119M +1,078,753 +11,847%
Wells Fargo
15
Wells Fargo
California
$119M -$17.2M -155,348 -14%
William Blair & Company
16
William Blair & Company
Illinois
$113M -$10.8M -97,701 -10%
Norges Bank
17
Norges Bank
Norway
$96.2M +$43.1M +390,063 +100%
Invesco
18
Invesco
Georgia
$91.1M -$32.4M -293,083 -28%
Fidelity International
19
Fidelity International
Bermuda
$90.4M +$524K +4,739 +0.7%
TA
20
Teachers Advisors
New York
$85M +$29M +262,717 +62%
Bank of America
21
Bank of America
North Carolina
$81.7M -$46.7M -422,628 -39%
American Century Companies
22
American Century Companies
Missouri
$79.5M +$5.15M +46,556 +8%
Millennium Management
23
Millennium Management
New York
$78.1M +$27M +244,019 +63%
Adage Capital Partners
24
Adage Capital Partners
Massachusetts
$74M +$44.2M +400,000 +200%
O
25
OppenheimerFunds
New York
$68M +$26.6M +240,860 +78%

SLXP Hedge Fund Activity: Q2 2014 in Review

308 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q2 2014, worth a combined $8.26B — up 21% from $6.82B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new SLXP positions and 46 closed out — a net gain of 4 holders — while 109 added to existing stakes and 127 trimmed.

The largest buyer was Viking Global Investors, adding an estimated $148M. The largest seller was Fidelity Investments, cutting an estimated $132M.

  • 308 institutional investors held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q2 2014, up from 304 in Q1 2014.
  • Funds reported $8.26B of SALIX PHARMACEUTICALS LTD DEL stock for Q2 2014, up 21% quarter-over-quarter.
  • 50 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q2 2014 and 46 closed out, a net change of +4 holders.
  • The largest SALIX PHARMACEUTICALS LTD DEL buyer in Q2 2014 was Viking Global Investors, an estimated $148M added.
  • The largest SALIX PHARMACEUTICALS LTD DEL seller in Q2 2014 was Fidelity Investments, an estimated $132M sold.

Based on aggregated 13F filings for Q2 2014.